Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZ97RW
|
|||
| Drug Name |
4D-310
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Fabry disease [ICD-11: 5C56.01; ICD-9: 272.7] | Phase 1/2 | [1] | |
| Company |
4D Molecular Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-galactosidase A (GLA) | Target Info | . | [2] |
| KEGG Pathway | Galactose metabolism | |||
| Glycerolipid metabolism | ||||
| Sphingolipid metabolism | ||||
| Glycosphingolipid biosynthesis - globo series | ||||
| Lysosome | ||||
| Pathwhiz Pathway | Sphingolipid Metabolism | |||
| Galactose Metabolism | ||||
| Reactome | Glycosphingolipid metabolism | |||
| WikiPathways | Sphingolipid metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04519749) An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of 4D Molecular Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.